Fenofibrate protects the intestine against ischemia/ reperfusion injury

1. Mallick IH, Yang W, Winslet MC, Seifalian AM. Ischemia-reperfusion injury of the intestine and protective strategies against injury. Dig Dis Sci. 2004; 49:1359-77.10.1023/B:DDAS.0000042232.98927.91Open DOISearch in Google Scholar

2. Kong SE, Blennerhassett LR, Heel KA, McCauley RD, Hall JC. Ischaemia-reperfusion injury to the intestine. Aust N Z J Surg. 1998; 68:554-61.10.1111/j.1445-2197.1998.tb02099.x9715130Search in Google Scholar

3. Girn HR, Ahilathirunayagam S, Mavor AI, Homer- Vanniasinkam S. Reperfusion syndrome: cellular mechanisms of microvascular dysfunction and potential therapeutic strategies. Vasc Endovascular Surg. 2007; 41:277-93.10.1177/153857440730451017704330Search in Google Scholar

4. Di Paola R, Cuzzocrea S. Peroxisome proliferatoractivated receptors ligands and ischemia-reperfusion injury. Naunyn Schmiedebergs Arch Pharmacol. 2007; 375:157-75.10.1007/s00210-007-0141-217394034Search in Google Scholar

5. Xu SQ, Li YH, Hu SH, Chen K, Dong LY. Effects of Wy14643 on hepatic ischemia reperfusion injury in rats. World J Gastroenterol. 2008; 14:6936-42.10.3748/wjg.14.6936277385619058328Open DOISearch in Google Scholar

6. Wayman NS, Ellis BL, Thiemermann C. Ligands of the peroxisome proliferator-activated receptor- PPAR-a reduce myocardial infarct size. Med Sci Monit. 2002; 8:BR243-7.Search in Google Scholar

7. Sivarajah A, Chatterjee PK, Hattori Y, Brown PA, Stewart KN, Todorovic Z, et al. Agonists of peroxisomeproliferator activated receptor-alpha (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat. Med Sci Monit. 2002; 8:BR532-9.Search in Google Scholar

8. Patel NS, di Paola R, Mazzon E, Britti D, Thiemermann C, Cuzzocrea S. Peroxisome proliferator-activated receptor-alpha contributes to the resolution of inflammation after renal ischemia/reperfusion injury. J Pharmacol Exp Ther. 2009; 328:635-43.10.1124/jpet.108.14619118997058Search in Google Scholar

9. Guzman-de la Garza FJ, Camara-Lemarroy CR, Alarcon- Galvan G, Cordero-Perez P, Munoz-Espinosa LE, Fernandez-Garza NE. Different patterns of intestinal response to injury after arterial, venous or arteriovenous occlusion in rats. World J Gastroenterol. 2009; 15:3901-7.10.3748/wjg.15.3901273125219701970Open DOISearch in Google Scholar

10. Pascher A, Klupp J. Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNFalpha inhibitors? BioDrugs. 19: 211-31, 2005.10.2165/00063030-200519040-0000216128605Open DOISearch in Google Scholar

11. Lee JH, Joe EH, Jou I. PPAR-alpha activators suppress STAT1 inflammatory signaling in lipopolysaccharideactivated rat glia. Neuroreport. 2005; 16:829-33.10.1097/00001756-200505310-0001015891579Search in Google Scholar

12. Delayre-Orthez C, Becker J, Guenon I, Lagente V, Auwerx J, Frossard N, et al. PPARalpha downregulates airway inflammation induced by lipopolysaccharide in the mouse. Respir Res. 2005; 6:91.10.1186/1465-9921-6-91119962516091136Open DOISearch in Google Scholar

13. Yang TL, Chen MF, Luo BL, Xie QY, Jiang JL, Li YJ. Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity. Naunyn Schmiedebergs Arch Pharmacol. 2005; 371:401-7.10.1007/s00210-005-1060-815915325Search in Google Scholar

14. Rosenson RS. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity (Silver Spring). 2009; 17:504-9.10.1038/oby.2008.53019023279Open DOISearch in Google Scholar

15. Camara-Lemarroy CR, Guzman-de la Garza FJ, Alarcon-Galvan G, Cordero-Perez P, Fernandez-Garza NE. The effects of NMDA receptor antagonists over intestinal ischemia/reperfusion injury in rats. Eur J Pharmacol. 2009; 621:78-85.10.1016/j.ejphar.2009.08.03819751722Search in Google Scholar

16. Schrader M, Fahimi HD. Peroxisomes and oxidative stress. Biochim Biophys Acta. 2006; 1763:1755-66.10.1016/j.bbamcr.2006.09.00617034877Search in Google Scholar

17. Betowski J, Wjcicka G, Mydlarczyk M, Jamroz A. The effect of peroxisome proliferator-activated receptors alpha (PPARalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON 1) activity. J Physiol Pharmacol. 2002; 53:463-75.Search in Google Scholar

18. Chen XR, Besson VC, Palmier B,Garcia Y, Plotkine M, Marchand-Leroux C. Neurological recoverypromoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J Neurotrauma. 2007; 24: 1119-31.10.1089/neu.2006.021617610352Open DOISearch in Google Scholar

19. Tkac I, Molcanyiova A, Javorsky M, Kozarova M. Fenofibrate treatment reduces circulating conjugated diene level and increases glutathione peroxidase activity. Pharmacol Res. 2006; 53:261-4. 10.1016/j.phrs.2005.12.00216420979Open DOISearch in Google Scholar